2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Parnis F, Suarez C, Yuasa T, Lalani A, Alva A, Bjarnason G, Choueiri T, Heng D. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology 2023, 84: 109-116. PMID: 36707357, DOI: 10.1016/j.eururo.2023.01.001.Peer-Reviewed Original ResearchConceptsInternational mRCC Database ConsortiumMetastatic renal cell carcinomaInternational mRCC Database Consortium risk groupIO combination therapyIpi-nivoOverall survivalRenal cell carcinomaCombination therapyTreatment durationRisk groupsCell carcinomaImmuno-oncologyTreatment cohortsInternational Metastatic Renal Cell Carcinoma Database Consortium modelStandard of care first-line treatmentVascular endothelial growth factor-targeted therapyFirst-line combination therapyMedian follow-up timePoor-risk groupEndpoint of OSFirst-line treatmentKaplan-Meier methodLog-rank testModel stratified patientsShort follow-up
2022
CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V, Wells C, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Pal S, Meza L, Donskov F, Beuselinck B, Ernst M, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 318-318. DOI: 10.1200/jco.2022.40.6_suppl.318.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabTreatment failureOverall survivalInternational Metastatic Renal Cell Carcinoma Database Consortium criteriaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupAdvanced renal cell carcinomaResponse rateActivity of cabozantinibClinically meaningful activityRenal cell carcinomaEndothelial growth factorCell histologySarcomatoid componentBone metastasesVEGF inhibitorsPoor riskCell carcinomaCabozantinibHazard ratioRisk groupsPatientsGrowth factorTherapyEarly lines